Wenjing Tian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wenjing Tian has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
Haibo Zhou
15 shared publicationsXiyun Ren
Department of Epidemiology, School of Public Health, Harbin Medical University, Harbin, P.R. China
14 shared publicationsXu Han
13 shared publicationsChuang Nie
Department of Epidemiology, School of Public Health, Harbin Medical University, Harbin, China
10 shared publicationsTianyu Liu
Department of Epidemiology School of Public Health, Harbin Medical University Harbin Heilongjiang Province P. R. China
7 shared publicationsYashuang Zhao
Department of Epidemiology, College of Public Health, Harbin Medical University, Harbin, China
6 shared publications
Latest Publications
- 4 April 2026
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Age at Menopause and Trajectories of Multimorbidity Progression to Mortality: A Multi‐State Analysis of UK Biobank Data
Objective: To investigate whether age at menopause is associated with the trajectory of multimorbidity progression. Design: A retrospective cohort study. Setting: The UK Biobank. Population: 121 017 postmenopausal women aged 40–69 years with complete baseline and menopausal data. Methods: Cox proportional hazards models were used to explore the associations between menopausal age and both multimorbidity and mortality. Multi‐state models were further employed to evaluate the association of menopausal age with transitions from a health state to the first chronic disease (FCD), to multimorbidity, and to mortality from each state. Main Outcome Measures: Multimorbidity (defined as ≥ 2 of 35 chronic conditions) and mortality. Results: Over a median follow‐up period of 8.6 years, 86 821 women developed the FCD, 42237 multimorbidity, and 10 527 participants died. In the multi‐state models analysis, from health to FCD, compared with women who experienced menopause after age 50 years, the risks increased by 32%, 14%, and 3% among women with premature, early, and relatively early menopause, respectively (HR = 1.32, 95% CI: 1.28–1.36; HR = 1.14, 95% CI: 1.11–1.17; HR = 1.03, 95% CI: 1.01–1.05). Similarly, for the transition from FCD to multimorbidity, the risks increased by 22% (HR = 1.22, 95% CI: 1.17–1.27), 13% (HR = 1.13, 95% CI: 1.09–1.16), and 6% (HR = 1.06, 95% CI: 1.03–1.08), respectively. Conclusions: Earlier menopause was associated with an increased risk of multimorbidity and mortality, mainly affecting two trajectories, from health to FCD and FCD to multimorbidity.
- 4 April 2026
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
Age at Menopause and Trajectories of Multimorbidity Progression to Mortality: A Multi‐State Analysis of UK Biobank Data
Objective: To investigate whether age at menopause is associated with the trajectory of multimorbidity progression. Design: A retrospective cohort study. Setting: The UK Biobank. Population: 121 017 postmenopausal women aged 40–69 years with complete baseline and menopausal data. Methods: Cox proportional hazards models were used to explore the associations between menopausal age and both multimorbidity and mortality. Multi‐state models were further employed to evaluate the association of menopausal age with transitions from a health state to the first chronic disease (FCD), to multimorbidity, and to mortality from each state. Main Outcome Measures: Multimorbidity (defined as ≥ 2 of 35 chronic conditions) and mortality. Results: Over a median follow‐up period of 8.6 years, 86 821 women developed the FCD, 42237 multimorbidity, and 10 527 participants died. In the multi‐state models analysis, from health to FCD, compared with women who experienced menopause after age 50 years, the risks increased by 32%, 14%, and 3% among women with premature, early, and relatively early menopause, respectively (HR = 1.32, 95% CI: 1.28–1.36; HR = 1.14, 95% CI: 1.11–1.17; HR = 1.03, 95% CI: 1.01–1.05). Similarly, for the transition from FCD to multimorbidity, the risks increased by 22% (HR = 1.22, 95% CI: 1.17–1.27), 13% (HR = 1.13, 95% CI: 1.09–1.16), and 6% (HR = 1.06, 95% CI: 1.03–1.08), respectively. Conclusions: Earlier menopause was associated with an increased risk of multimorbidity and mortality, mainly affecting two trajectories, from health to FCD and FCD to multimorbidity.
- Open Access
- 7 April 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-9
Circadian rest-activity rhythms and multimorbidity and mortality risks among menopausal women: a trajectory analysis of a UK Biobank cohort
Menopausal women undergo substantial physiological changes that can impact their overall health. We examined relationships between circadian rest-activity rhythms (CRARs) and multimorbidity progression in this population. We used UK Biobank data, involving 10,138 participants, who were initially free of chronic conditions. We primarily focused on the relative amplitude (RA) of CRARs, tracking incident first chronic conditions (FCC), multimorbidity, and all-cause mortality. Multimorbidity was indicated by the presence of any 2/35 chronic conditions during the follow-up period. We used a multi-state model to assess the RA impact on the multimorbidity progression trajectory, encompassing transition from health to an FCC, to consequent multimorbidity, and ultimately to mortality, in parallel with sensitivity analyses to ensure results stability and reliability. During a mean 8.13-year follow-up period, we identified 855 incident multimorbidity cases and recorded 88 deaths. In a multi-state model, a lower RA was associated with an increased risk of transition from health to FCC onset [hazard ratio (HR): 1.18, 95% confidence interval (CI): 1.07–1.31] and also from an FCC to multimorbidity development (HR: 1.34, 95% CI: 1.12–1.61), even after adjusting for several confounding factors. Among menopausal women, circadian rhythm disturbance increased the risk of transitioning from health to a single chronic condition, as well as transitioning from a single chronic condition to multimorbidity.
- 7 April 2025
- Published by Springer Nature in BMC Public Health
- Vol. 25 (1) , 1-9
Open AccessCircadian rest-activity rhythms and multimorbidity and mortality risks among menopausal women: a trajectory analysis of a UK Biobank cohort
Menopausal women undergo substantial physiological changes that can impact their overall health. We examined relationships between circadian rest-activity rhythms (CRARs) and multimorbidity progression in this population. We used UK Biobank data, involving 10,138 participants, who were initially free of chronic conditions. We primarily focused on the relative amplitude (RA) of CRARs, tracking incident first chronic conditions (FCC), multimorbidity, and all-cause mortality. Multimorbidity was indicated by the presence of any 2/35 chronic conditions during the follow-up period. We used a multi-state model to assess the RA impact on the multimorbidity progression trajectory, encompassing transition from health to an FCC, to consequent multimorbidity, and ultimately to mortality, in parallel with sensitivity analyses to ensure results stability and reliability. During a mean 8.13-year follow-up period, we identified 855 incident multimorbidity cases and recorded 88 deaths. In a multi-state model, a lower RA was associated with an increased risk of transition from health to FCC onset [hazard ratio (HR): 1.18, 95% confidence interval (CI): 1.07–1.31] and also from an FCC to multimorbidity development (HR: 1.34, 95% CI: 1.12–1.61), even after adjusting for several confounding factors. Among menopausal women, circadian rhythm disturbance increased the risk of transitioning from health to a single chronic condition, as well as transitioning from a single chronic condition to multimorbidity.
- Open Access
- 26 December 2024
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 54, 101272
Using primary and routinely collected data to determine prevalence and patterns of multimorbidity in rural China: a representative cross-sectional study of 6474 Chinese adults
- 26 December 2024
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 54, 101272
Open AccessUsing primary and routinely collected data to determine prevalence and patterns of multimorbidity in rural China: a representative cross-sectional study of 6474 Chinese adults
- 29 June 2023
- Published by Springer Nature in Biochemical Genetics
- Vol. 62 (1) , 504-529
Comprehensive Analysis on Prognostic Signature Based on T Cell-Mediated Tumor Killing Related Genes in Gastric Cancer
Although immunotherapy is a valuable treatment for gastric cancer (GC), identifying the patients who would benefit most from this approach presents a challenge. In this study, GC patients were divided into two subtypes by consensus clustering according to T cell-mediated tumor killing related genes (TTKRGs), and there were significant differences in tumor-infiltrating immune cells, signaling pathways, and gene expression of immunomodulators and inhibitory immune checkpoints between the two subtypes. Then, we developed an individualized signature based on TTKRGs, and its clinical and predictive value in GC patients for chemotherapeutic and immunotherapeutic responses was assessed. We confirmed the expression levels of signature genes in GC tumor tissue using quantitative real-time polymerase chain reaction (qRT-PCR). Additionally, to improve the accuracy of GC prognosis predictions, we established a nomogram. We further identified some compounds as sensitive drugs targeting GC risk groups. The signature showed significant predictive ability across RNA-seq, microarray, and qRT-PCR cohorts, which could assist in predicting survival, immunotherapeutic and chemotherapeutic outcomes in GC patients.
- 29 June 2023
- Published by Springer Nature in Biochemical Genetics
- Vol. 62 (1) , 504-529
Comprehensive Analysis on Prognostic Signature Based on T Cell-Mediated Tumor Killing Related Genes in Gastric Cancer
Although immunotherapy is a valuable treatment for gastric cancer (GC), identifying the patients who would benefit most from this approach presents a challenge. In this study, GC patients were divided into two subtypes by consensus clustering according to T cell-mediated tumor killing related genes (TTKRGs), and there were significant differences in tumor-infiltrating immune cells, signaling pathways, and gene expression of immunomodulators and inhibitory immune checkpoints between the two subtypes. Then, we developed an individualized signature based on TTKRGs, and its clinical and predictive value in GC patients for chemotherapeutic and immunotherapeutic responses was assessed. We confirmed the expression levels of signature genes in GC tumor tissue using quantitative real-time polymerase chain reaction (qRT-PCR). Additionally, to improve the accuracy of GC prognosis predictions, we established a nomogram. We further identified some compounds as sensitive drugs targeting GC risk groups. The signature showed significant predictive ability across RNA-seq, microarray, and qRT-PCR cohorts, which could assist in predicting survival, immunotherapeutic and chemotherapeutic outcomes in GC patients.
- Open Access
Association between EPHA5 methylation status in peripheral blood leukocytes and the risk and prognosis of gastric cancer
Purpose Altered DNA methylation, genetic alterations, and environmental factors are involved in tumorigenesis. As a tumor suppressor gene, abnormal EPHA5 methylation was found in gastric cancer (GC) tissues and was linked to the initiation, progression and prognosis of GC. In this study, the EPHA5 methylation level in peripheral blood leukocytes (PBLs) was detected to explore its relationship with GC risk and prognosis. Methods A total of 366 GC cases and 374 controls were selected as the subjects of this study to collect their environmental factors, and the EPHA5 methylation status was detected through the methylation-sensitive high-resolution melting method. Logistic regression analysis was utilized to evaluate the associations among EPHA5 methylation, environmental factors and GC risk. Meanwhile, the propensity score (PS) was used to adjust the imbalance of some independent variables. Results After PS adjustment, EPHA5 Pm (positive methylation) was more likely to increase the GC risk than EPHA5 Nm (negative methylation) (ORb = 1.827, 95% CI [1.202–2.777], P = 0.005). EPHA5 Pm had a more significant association with GC risk in the elderly (ORa = 2.785, 95% CI [1.563–4.961], P = 0.001) and H. pylori-negative groups (ORa = 2.758, 95% CI [1.369–5.555], P = 0.005). Moreover, the combined effects of EPHA5 Pm and H. pylori infection (ORca = 3.543, 95% CI [2.233–5.621], P < 0.001), consumption of alcohol (ORca = 2.893, 95% CI [1.844–4.539], P < 0.001), and salty food intake (ORca = 4.018, 95% CI [2.538–6.362], P < 0.001) on increasing the GC risk were observed. In addition, no convincing association was found between EPHA5 Pm and the GC prognosis. Conclusions EPHA5 methylation in PBLs and its combined effects with environmental risk factors are related to the GC risk.
Open AccessAssociation between EPHA5 methylation status in peripheral blood leukocytes and the risk and prognosis of gastric cancer
Purpose Altered DNA methylation, genetic alterations, and environmental factors are involved in tumorigenesis. As a tumor suppressor gene, abnormal EPHA5 methylation was found in gastric cancer (GC) tissues and was linked to the initiation, progression and prognosis of GC. In this study, the EPHA5 methylation level in peripheral blood leukocytes (PBLs) was detected to explore its relationship with GC risk and prognosis. Methods A total of 366 GC cases and 374 controls were selected as the subjects of this study to collect their environmental factors, and the EPHA5 methylation status was detected through the methylation-sensitive high-resolution melting method. Logistic regression analysis was utilized to evaluate the associations among EPHA5 methylation, environmental factors and GC risk. Meanwhile, the propensity score (PS) was used to adjust the imbalance of some independent variables. Results After PS adjustment, EPHA5 Pm (positive methylation) was more likely to increase the GC risk than EPHA5 Nm (negative methylation) (ORb = 1.827, 95% CI [1.202–2.777], P = 0.005). EPHA5 Pm had a more significant association with GC risk in the elderly (ORa = 2.785, 95% CI [1.563–4.961], P = 0.001) and H. pylori-negative groups (ORa = 2.758, 95% CI [1.369–5.555], P = 0.005). Moreover, the combined effects of EPHA5 Pm and H. pylori infection (ORca = 3.543, 95% CI [2.233–5.621], P < 0.001), consumption of alcohol (ORca = 2.893, 95% CI [1.844–4.539], P < 0.001), and salty food intake (ORca = 4.018, 95% CI [2.538–6.362], P < 0.001) on increasing the GC risk were observed. In addition, no convincing association was found between EPHA5 Pm and the GC prognosis. Conclusions EPHA5 methylation in PBLs and its combined effects with environmental risk factors are related to the GC risk.
- 10 August 2022
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 52 (12) , 1365-1374
Risk factors associated with cardiovascular mortality among gastric cancer patients: a population-based analysis
Cancer patients were found at a high risk of death from cardiovascular disease. This study aims to assess cardiovascular mortality risk and identify the potential risk factors associated with cardiovascular mortality among gastric cancer patients. Gastric cancer patients were collected from the Surveillance Epidemiology and End Results database during 1975–2016. Standardized mortality ratios were calculated to compare cardiovascular mortality rates between gastric cancer patients and the general US population. Univariable Cox analysis and multivariable stepwise Cox analysis were adopted to identify the potential risk factors for cardiovascular disease death after gastric cancer diagnosis. There were 10 886 cardiovascular disease deaths identified among 165 433 individuals with gastric cancer observed for 410207.20 person-years. Gastric cancer patients were at a higher cardiovascular disease mortality risk (standardized mortality ratio = 3.35, 95% confidence interval: 3.24–3.47, P < 0.05). The study showed that older age at diagnosis (>80 years vs. 0–69 years, hazard ratio = 7.05, 95% confidence interval: 6.66–7.46, P < 0.001; 70–80 years vs. 0–69 years, hazard ratio = 3.35, 95% confidence interval: 3.19–3.53, P < 0.001), male sex (vs. female, hazard ratio = 1.39, 95% confidence interval: 1.33–1.45, P < 0.001), black race (vs. white, hazard ratio = 1.31, 95% confidence interval: 1.24–1.38, P < 0.001), without a partner (divorced/separated vs. married/partnered, hazard ratio = 1.35, 95% confidence interval: 1.25–1.45, P < 0.001; single vs. married/partnered, hazard ratio = 1.20, 95% confidence interval: 1.12–1.29, P < 0.001; widowed vs. married/partnered, hazard ratio = 1.41, 95% confidence interval: 1.34–1.48, P < 0.001), living in the northern plains (vs. pacific coast, hazard ratio = 1.23, 95% confidence interval: 1.16–1.29, P < 0.001) and surgery not performed (vs. performed, hazard ratio = 1.70, 95% confidence interval: 1.61–1.79, P < 0.001) were significantly associated with increased risk of cardiovascular disease death. Compared with patients with localized stage, distant staged patients were less likely to die of cardiovascular disease (hazard ratio = 0.88, 95% confidence interval: 0.83–0.94, P < 0.001). Gastric cancer patients were at an increased risk of cardiovascular disease death. Older age at diagnosis, male sex, black race, without a partner, living in the northern plains and surgery not performed were significantly associated with cardiovascular disease death after gastric cancer diagnosis.
- 10 August 2022
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 52 (12) , 1365-1374
Risk factors associated with cardiovascular mortality among gastric cancer patients: a population-based analysis
Cancer patients were found at a high risk of death from cardiovascular disease. This study aims to assess cardiovascular mortality risk and identify the potential risk factors associated with cardiovascular mortality among gastric cancer patients. Gastric cancer patients were collected from the Surveillance Epidemiology and End Results database during 1975–2016. Standardized mortality ratios were calculated to compare cardiovascular mortality rates between gastric cancer patients and the general US population. Univariable Cox analysis and multivariable stepwise Cox analysis were adopted to identify the potential risk factors for cardiovascular disease death after gastric cancer diagnosis. There were 10 886 cardiovascular disease deaths identified among 165 433 individuals with gastric cancer observed for 410207.20 person-years. Gastric cancer patients were at a higher cardiovascular disease mortality risk (standardized mortality ratio = 3.35, 95% confidence interval: 3.24–3.47, P < 0.05). The study showed that older age at diagnosis (>80 years vs. 0–69 years, hazard ratio = 7.05, 95% confidence interval: 6.66–7.46, P < 0.001; 70–80 years vs. 0–69 years, hazard ratio = 3.35, 95% confidence interval: 3.19–3.53, P < 0.001), male sex (vs. female, hazard ratio = 1.39, 95% confidence interval: 1.33–1.45, P < 0.001), black race (vs. white, hazard ratio = 1.31, 95% confidence interval: 1.24–1.38, P < 0.001), without a partner (divorced/separated vs. married/partnered, hazard ratio = 1.35, 95% confidence interval: 1.25–1.45, P < 0.001; single vs. married/partnered, hazard ratio = 1.20, 95% confidence interval: 1.12–1.29, P < 0.001; widowed vs. married/partnered, hazard ratio = 1.41, 95% confidence interval: 1.34–1.48, P < 0.001), living in the northern plains (vs. pacific coast, hazard ratio = 1.23, 95% confidence interval: 1.16–1.29, P < 0.001) and surgery not performed (vs. performed, hazard ratio = 1.70, 95% confidence interval: 1.61–1.79, P < 0.001) were significantly associated with increased risk of cardiovascular disease death. Compared with patients with localized stage, distant staged patients were less likely to die of cardiovascular disease (hazard ratio = 0.88, 95% confidence interval: 0.83–0.94, P < 0.001). Gastric cancer patients were at an increased risk of cardiovascular disease death. Older age at diagnosis, male sex, black race, without a partner, living in the northern plains and surgery not performed were significantly associated with cardiovascular disease death after gastric cancer diagnosis.
- 6 June 2022
- Published by Taylor & Francis in Cancer Investigation
- Vol. 40 (7) , 604-620
Risk and Prognosis of Second Primary Cancers among Ovarian Cancer Patients, Based on SEER Database
The purposes of the present study were to elucidate the risk and prognostic effect of second primary cancers (SPCs) development, as well as the factors influencing the prognosis of OC patients with SPCs. A statistically significant increase in SPCs risk was observed among OC patients during 2004-2015. The independent factors were used to construct the SPCs-prediction nomogram and the OS-prediction nomogram. Both nomogram were subjected to internal validation and performed well. OC patients with SPCs have a better prognosis than patients without SPCs. Propensity score matching (PSM) was applied to reduce confounding.
- 6 June 2022
- Published by Taylor & Francis in Cancer Investigation
- Vol. 40 (7) , 604-620
Risk and Prognosis of Second Primary Cancers among Ovarian Cancer Patients, Based on SEER Database
The purposes of the present study were to elucidate the risk and prognostic effect of second primary cancers (SPCs) development, as well as the factors influencing the prognosis of OC patients with SPCs. A statistically significant increase in SPCs risk was observed among OC patients during 2004-2015. The independent factors were used to construct the SPCs-prediction nomogram and the OS-prediction nomogram. Both nomogram were subjected to internal validation and performed well. OC patients with SPCs have a better prognosis than patients without SPCs. Propensity score matching (PSM) was applied to reduce confounding.
- Open Access
- 19 April 2022
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 9, 872932
Identification of Tumor Microenvironment and DNA Methylation-Related Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses in Cervical Cancer
Background: Tumor microenvironment (TME) has been reported to have a strong association with tumor progression and therapeutic outcome, and epigenetic modifications such as DNA methylation can affect TMB and play an indispensable role in tumorigenesis. However, the potential mechanisms of TME and DNA methylation remain unclear in cervical cancer (CC).Methods: The immune and stromal scores of TME were generated by the ESTIMATE algorithm for CC patients in The Cancer Genome Atlas (TCGA) database. The TME and DNA methylation-related genes were identified by the integrative analysis of DNA promoter methylation and gene expression. The least absolute shrinkage and selection operator (LASSO) Cox regression was performed 1,000 times to further identify a nine-gene TME and DNA methylation-related prognostic signature. The signature was further validated in Gene Expression Omnibus (GEO) dataset. Then, the identified signature was integrated with the Federation International of Gynecology and Obstetrics (FIGO) stage to establish a composite prognostic nomogram.Results: CC patients with high immunity levels have better survival than those with low immunity levels. Both in the training and validation datasets, the risk score of the signature was an independent prognosis factor. The composite nomogram showed higher accuracy of prognosis and greater net benefits than the FIGO stage and the signature. The high-risk group had a significantly higher fraction of genome altered than the low-risk group. Eleven genes were significantly different in mutation frequencies between the high- and low-risk groups. Interestingly, patients with mutant TTN had better overall survival (OS) than those with wild type. Patients in the low-risk group had significantly higher tumor mutational burden (TMB) than those in the high-risk group. Taken together, the results of TMB, immunophenoscore (IPS), and tumor immune dysfunction and exclusion (TIDE) score suggested that patients in the low-risk group may have greater immunotherapy benefits. Finally, four drugs (panobinostat, lenvatinib, everolimus, and temsirolimus) were found to have potential therapeutic implications for patients with a high-risk score.Conclusions: Our findings highlight that the TME and DNA methylation-related prognostic signature can accurately predict the prognosis of CC and may be important for stratified management of patients and precision targeted therapy.
- 19 April 2022
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 9, 872932
Open AccessIdentification of Tumor Microenvironment and DNA Methylation-Related Prognostic Signature for Predicting Clinical Outcomes and Therapeutic Responses in Cervical Cancer
Background: Tumor microenvironment (TME) has been reported to have a strong association with tumor progression and therapeutic outcome, and epigenetic modifications such as DNA methylation can affect TMB and play an indispensable role in tumorigenesis. However, the potential mechanisms of TME and DNA methylation remain unclear in cervical cancer (CC).Methods: The immune and stromal scores of TME were generated by the ESTIMATE algorithm for CC patients in The Cancer Genome Atlas (TCGA) database. The TME and DNA methylation-related genes were identified by the integrative analysis of DNA promoter methylation and gene expression. The least absolute shrinkage and selection operator (LASSO) Cox regression was performed 1,000 times to further identify a nine-gene TME and DNA methylation-related prognostic signature. The signature was further validated in Gene Expression Omnibus (GEO) dataset. Then, the identified signature was integrated with the Federation International of Gynecology and Obstetrics (FIGO) stage to establish a composite prognostic nomogram.Results: CC patients with high immunity levels have better survival than those with low immunity levels. Both in the training and validation datasets, the risk score of the signature was an independent prognosis factor. The composite nomogram showed higher accuracy of prognosis and greater net benefits than the FIGO stage and the signature. The high-risk group had a significantly higher fraction of genome altered than the low-risk group. Eleven genes were significantly different in mutation frequencies between the high- and low-risk groups. Interestingly, patients with mutant TTN had better overall survival (OS) than those with wild type. Patients in the low-risk group had significantly higher tumor mutational burden (TMB) than those in the high-risk group. Taken together, the results of TMB, immunophenoscore (IPS), and tumor immune dysfunction and exclusion (TIDE) score suggested that patients in the low-risk group may have greater immunotherapy benefits. Finally, four drugs (panobinostat, lenvatinib, everolimus, and temsirolimus) were found to have potential therapeutic implications for patients with a high-risk score.Conclusions: Our findings highlight that the TME and DNA methylation-related prognostic signature can accurately predict the prognosis of CC and may be important for stratified management of patients and precision targeted therapy.